MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

INKT Interest Expense

Cost of servicing the company's debt during the period.

MiNK Therapeutics, Inc.NASDAQ: INKT

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How INKT compares with its peers on the latest reported figures

  • INKT's LTM Mar 2026 interest expense of $0 is the 7th highest of the 9 companies compared; the peer median is $194.43K.
INKT Competitors Peer median
Interest Expense for INKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$4.55M -10.3%—21.7%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$904K +6.5%—39.4%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$728K +195.9%-40.2%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$313.51K —-42.5%94.1%
OSTXOS Therapies IncorporatedLTM Mar 2026$75.34K -93.8%——
VTVTvTv Therapeutics Inc.LTM Mar 2026$6K —-26.3%0.0%
INKTMiNK Therapeutics, Inc.LTM Mar 2026$0 ———
EQEquillium, Inc.LTM Mar 2026$0 ———
GANXGain Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding INKT) $194.43K-1.9%-40.2%30.6%

Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue77.96K121.75K204.62K215.44K181.75K
Gross Profit(77.96K)(121.75K)(204.62K)(215.44K)(181.75K)
Gross Margin—————
Research & Development13.97M23.12M15.49M6.34M5.76B
Selling, General & Admin4.56M7.71M7.43M4.1M6.73B
Operating Expenses18.53M30.83M22.72M10.43M12.31M
Depreciation & Amortization77.96K121.75K204.62K215.44K181.75K
EBITDA(27.7M)(27.87M)(22.25M)(10.57M)(12.31M)
EBITDA Margin—————
Operating Income(18.61M)(30.95M)(22.92M)(10.65M)(12.49M)
Operating Margin—————
Interest Income2.43K253.32K463.26K172.57K180.25K
Interest Expense2.43M253.32K000
Other Income / Expenses(11.61M)2.96M463.25K(134.56K)(6.96K)
Income Before Tax(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Net Margin—————
EPS (Basic)(9.03)(8.31)(6.54)(2.90)(2.93)
EPS (Diluted)(9.03)(8.31)(6.54)(2.80)(2.93)
Weighted Avg Shares3.35M3.37M3.44M3.74M4.27M
Weighted Avg Shares (Diluted)3.35M3.37M3.44M3.86M4.27M

MiNK Therapeutics, Inc.

NASDAQ:INKT

Intrinsic Alpha fair value

Locked

Current Price

$10.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.